Peer Exchange
March 26, 2018 –
Peter L. Salgo, MD; Michael G. Sension, MD; Elly Fatehi, PharmD, MPH; and Jeffrey D. Dunn, PharmD, MBA, examine the potential for collaboration among payers and providers to achieve good clinical outcomes in HIV treatment that are cost effective.
March 19, 2018 –
Peter L. Salgo, MD; Jeffrey D. Dunn, PharmD, MBA; Michael G. Sension, MD; and Elly Fatehi, PharmD, MPH, offer insight regarding the potential impact that tighter management of HIV agents would have on clinical decision making.
March 19, 2018 –
Peter L. Salgo, MD; Jeffrey D. Dunn, PharmD, MBA; Michael G. Sension, MD; and Elly Fatehi, PharmD, MPH, discuss the challenges with payer management of HIV therapies.
March 12, 2018 –
Peter L. Salgo, MD; Jeffrey D. Dunn, PharmD, MBA; Michael G. Sension, MD; and Elly Fatehi, PharmD, MPH, discuss the difficulty in finding a common ground with clinical decision making and cost control for HIV therapies.
March 12, 2018 –
Peter L. Salgo, MD; Elly Fatehi, PharmD, MPH; Jeffrey D. Dunn, PharmD, MBA; and Michael G. Sension, MD, discuss the connection between poor compliance and development of resistance in patients with HIV.
March 05, 2018 –
Peter L. Salgo, MD; Elly Fatehi, PharmD, BCPS; Michael Sension, MD; and Jeffrey Dunn, PharmD, explore scenarios that require HIV treatments that fall outside of the guideline recommendations for most patients.
March 05, 2018 –
Peter L. Salgo, MD; Michael Sension, MD; Jeffrey Dunn, PharmD; and Elly Fatehi, PharmD, BCPS, offer their perspectives on the rationale for initiating HIV therapy and testing for resistance at diagnosis.
February 27, 2018 –
Peter L. Salgo, MD; Michael Sension, MD; Jeffrey Dunn, PharmD; and Elly Fatehi, PharmD, BCPS, examine the prevalence of HIV and ways to control costs without compromising care.
February 27, 2018 –
Peter L. Salgo, MD; Michael Sension, MD; and Jeffrey Dunn, PharmD, discuss the need for more individualized therapy in HIV and the impact of guideline updates on payer decisions.
February 21, 2018 –
Peter L. Salgo, MD; Michael Sension, MD; Jeffrey Dunn, PharmD; and Elly Fatehi, PharmD, MPH, review the updates to the HHS treatment guideline for most people with human immunodeficiency virus.
